← Back to Search

Other

3APS for Alzheimer's Disease

Phase 3
Waitlist Available
Research Sponsored by Bellus Health Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of probable Alzheimer's disease based on the NINCDS-ADRDA criteria
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing whether a new drug can improve symptoms in people with Alzheimer's disease.

Who is the study for?
This trial is for men and women aged 50 or older with mild to moderate Alzheimer's, as diagnosed by specific criteria. Participants must have a caregiver, be fluent in English, French, or Spanish, and have been on stable Alzheimer's medication for at least 4 months. Those with other dementia causes or significant medical conditions cannot join.Check my eligibility
What is being tested?
The study is testing the effectiveness and safety of a drug called 3APS against a placebo in patients with mild to moderate Alzheimer's disease. It's a Phase III trial where participants are randomly given either the real drug or an inactive pill.See study design
What are the potential side effects?
While specific side effects of 3APS aren't listed here, common ones in trials like this may include gastrointestinal issues, headaches, dizziness, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Alzheimer's disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.
The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.

Find a Location

Who is running the clinical trial?

Bellus Health IncLead Sponsor
15 Previous Clinical Trials
4,322 Total Patients Enrolled
Bellus Health Inc. - a GSK companyLead Sponsor
17 Previous Clinical Trials
4,388 Total Patients Enrolled

Media Library

3APS (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00088673 — Phase 3
Alzheimer's Disease Research Study Groups:
Alzheimer's Disease Clinical Trial 2023: 3APS Highlights & Side Effects. Trial Name: NCT00088673 — Phase 3
3APS (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00088673 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current openings for patients who want to participate in this clinical trial?

"Although this particular clinical trial is not presently looking for patients, according to the data hosted on clinicaltrials.gov, it was last updated on February 27th, 2007. There are 562 other trials actively recruiting participants."

Answered by AI

Does the FDA sanction this medication?

"This potential medication has received a safety score of three from our team at Power. This is due to this being a Phase 3 trial, which means that there is both some evidence of efficacy as well as multiple rounds of data supporting its safety."

Answered by AI

In how many different locations is this research project being conducted today?

"At the moment, 67 different medical facilities are recruiting patients for this study. The primary locations are Springfield, Cleveland and Verdun (Montreal); however, there are also other participating clinics in a variety of cities. If you enroll, it is best to choose the closest location to reduce travel time and effort."

Answered by AI

Who else is applying?

What site did they apply to?
Radiant Research
Clinical Pharmaceuticals Trials, Inc.
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
2004. "Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00088673.
All > Alzheimer Disease > Alzheimers Disease
~46 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top